AXDX (Accelerate Diagnostics, Inc) יחס שווי שוק לשווי בספרים

PhenoTest system deliveries provide a tangible impact, while rapid diagnostic system solutions create a steady stream of recurring payments. The price-to-book ratio reflects a premium over assets, with the current level sitting around -0.01. Accelerate Diagnostics (AXDX) revenue stability is supported by the sale of instruments and reagents for rapid antibiotic selection in hospitals.

Laboratory diagnostics automation at Accelerate Diagnostics (AXDX) requires significant capital expenditures in the technology stack. This indicator compares the company's market value to its net assets, revealing the extent of the premium paid for the business. By analyzing the historical trend of the price-to-book (P/B) ratio, an investor can see how closely share prices align with the actual return on equity. An increase in this metric without accelerated earnings signals overheating, while low values confirm a conservative and sustainable asset valuation.